Table 2. Pulmonary Outcomes According to PAD3/4 Cross-Reactive Antibody Status.
| Characteristic | Total (n = 176) | No anti-PAD(n = 120) | Anti-PAD4 only(n = 37) | Anti-PAD3/4XR(n = 19) | p-value* |
| Any ILD, n (%) | 58 (33) | 35 (29) | 10 (27) | 13 (68) | 0.001 |
| Any GGO, n (%) | 22 (13) | 11 (10) | 6 (16) | 5 (28) | 0.047 |
| Any R/TB/HC, n (%) | 36 (22) | 21 (19) | 8 (22) | 7 (39) | 0.045 |
| ILD Score, units (0–32) | 0 (0–2; range 0–10) | 0 (0–2; range 0–6) | 0 (0–2; range 0–10) | 2 (0–2; range 0–10) | 0.020 |
| Emphysema score, units (0–32) | 0 (0–0; range 0–6) | 0 (0–0; range 0–6) | 0 (0–0; range 0–4) | 0 (0–0; range 0–2) | 0.77 |
| Any PFT Abnormality (n = 158), n (%) | 44 (28) | 33 (29) | 9 (29) | 2 (13) | 0.23 |
| Any PFT Restriction or Impaired Diffusion, n (%) | 30 (21) | 21 (22) | 8 (27) | 1 (8) | 0.46 |
| Any respiratory symptoms (n = 168), n (%) | 69 (41) | 47 (40) | 13 (38) | 9 (53) | 0.43 |
| Number of respiratory symptoms | 0 (0–1; range 0–4) | 0 (0–1; range 0–4) | 0 (0–2; range 0–4) | 1 (0–1; range 0–3) | 0.55 |
Values are median (interquartile range) unless otherwise noted.
*p-values are for the comparison of the no anti-PAD vs. anti-PAD3/4XR groups.
PAD = peptidyl-arginine deiminase; anti-PAD3/4XR = anti-PAD3/4 Cross-Reactive antibodies; RA = rheumatoid arthritis; ILD = interstitial lung disease; GGO = ground glass opacification; R/TB/HC = reticulation/traction bronchiectasis/honeycombing; PFT = pulmonary function testing; Impaired Diff = impaired diffusion.